Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Rx Benefit Is "Net Negative" Among Seniors, Republican Pollster Says

This article was originally published in The Pink Sheet Daily

Executive Summary

A clear explanation of the law has not been communicated, Bill McInturff says. AARP will begin airing a commercial by the end of the month to help explain the Medicare Rx benefit.

You may also be interested in...



Seniors Should Understand "Consequences" Of Leaving Medicare Rx, Governors Say

"If an individual doesn't like their prescription drug plan, opts out of it…Medicaid is not going to be there," NGA's Matthew Salo says. States will likely have to establish a safety net for dual eligibles who opt out of Medicare.

Seniors Should Understand "Consequences" Of Leaving Medicare Rx, Governors Say

"If an individual doesn't like their prescription drug plan, opts out of it…Medicaid is not going to be there," NGA's Matthew Salo says. States will likely have to establish a safety net for dual eligibles who opt out of Medicare.

Manufacturers Respond To AARP Concerns On Pricing, But Decline To Take Pledge

Merck, GSK, Lilly and PhRMA will not voluntarily limit price increases as AARP requested. The tone of the responses, the seniors' group noted, has been cooperative. Several manufacturers suggested a meeting with AARP as the next step.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059057

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel